Display options
Cite
Vučić Lovrenčić M, Pibernik-Okanović M, Šekerija M, et al. Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual. Int J Endocrinol. 2015;2015:210406doi: 10.1155/2015/210406.
Vučić Lovrenčić, M., Pibernik-Okanović, M., Šekerija, M., Prašek, M., Ajduković, D., Kos, J., & Hermanns, N. (2015). Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual. International journal of endocrinology, 2015210406. https://doi.org/10.1155/2015/210406
Vučić Lovrenčić, Marijana, et al. "Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual." International journal of endocrinology vol. 2015 (2015): 210406. doi: https://doi.org/10.1155/2015/210406
Vučić Lovrenčić M, Pibernik-Okanović M, Šekerija M, Prašek M, Ajduković D, Kos J, Hermanns N. Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual. Int J Endocrinol. 2015;2015:210406. doi: 10.1155/2015/210406. Epub 2015 Aug 10. PMID: 26347775; PMCID: PMC4546977.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2015;2015:210406. doi: 10.1155/2015/210406. Epub 2015 Aug 10.

Improvement in Depressive Symptoms Is Associated with Reduced Oxidative Damage and Inflammatory Response in Type 2 Diabetic Patients with Subsyndromal Depression: The Results of a Randomized Controlled Trial Comparing Psychoeducation, Physical Exercise, and Enhanced Treatment as Usual.

International journal of endocrinology

Marijana Vučić Lovrenčić, Mirjana Pibernik-Okanović, Mario Šekerija, Manja Prašek, Dea Ajduković, Jadranka Kos, Norbert Hermanns

Affiliations

  1. Department of Laboratory Medicine, Merkur University Hospital, Zaj?eva 19, 10000 Zagreb, Croatia.
  2. Vuk Vrhovac University Clinic for Diabetes, Merkur University Hospital, Zaj?eva 19, 10000 Zagreb, Croatia.
  3. Croatian Institute of Public Health, Rockefellerova 7, 10000 Zagreb, Croatia.
  4. Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM GmbH), Theodor Klotzbücher Strasse 12, 97980 Bad Mergentheim, Germany.

PMID: 26347775 PMCID: PMC4546977 DOI: 10.1155/2015/210406

Abstract

Aims. To examine one-year changes in oxidative damage and inflammation level in type 2 diabetic patients undergoing behavioral treatment for subsyndromal depression. Materials and Methods. A randomized controlled comparison of psychoeducation (A), physical exercise (B), and enhanced treatment as usual (C) was performed in 209 eligible subjects in a tertiary diabetes care setting. Depressive symptoms (primary outcome) and selected biomarkers of oxidative damage and inflammation (secondary outcomes) were assessed at baseline and six- and twelve-month follow-up. Results. Out of the 74, 67, and 68 patients randomised into groups A, B, and C, respectively, 201 completed the interventions, and 179 were analysed. Participants in all three groups equally improved in depressive symptoms from baseline to one-year follow-up (repeated measures ANOVA; F = 12.51, p < 0.0001, η (2) = 0.07). Urinary 8-oxo-deoxyguanosine (u-8-oxodG) decreased (F = 10.66, p < 0.0001, η (2) = 0.06), as did sialic acid and leukocytes (F = 84.57, η (2) = 0.32 and F = 12.61, η (2) = 0.07, resp.; p < 0.0001), while uric acid increased (F = 12.53, p < 0.0001, η (2) = 0.07) in all subjects during one year. Improvement of depressive symptoms at 6 months significantly predicted one-year reduction in u-8-oxodG (β = 0.15, p = 0.044). Conclusion. Simple behavioral interventions are capable not only of alleviating depressive symptoms, but also of reducing the intensity of damaging oxidative/inflammatory processes in type 2 diabetic patients with subsyndromal depression. This trial is registered with ISRCTN05673017.

References

  1. Psychiatry Res. 2012 Dec 30;200(2-3):318-22 - PubMed
  2. Brain Behav Immun. 2014 Aug;40:235-43 - PubMed
  3. Diabetes Care. 2013 Sep;36(9):2551-8 - PubMed
  4. Diabetes Res Clin Pract. 2014 Aug;105(2):141-50 - PubMed
  5. Psychosom Med. 2001 Jul-Aug;63(4):619-30 - PubMed
  6. J Affect Disord. 2013 Jul;149(1-3):355-62 - PubMed
  7. Gen Hosp Psychiatry. 2008 Nov-Dec;30(6):509-14 - PubMed
  8. Kidney Int. 2011 Aug;80(4):415-22 - PubMed
  9. BMC Med. 2013 Sep 12;11:200 - PubMed
  10. Obes Rev. 2011 Jun;12(6):449-58 - PubMed
  11. Biochim Biophys Acta. 2014 Sep;1840(9):2709-29 - PubMed
  12. J Diabetes Complications. 2008 Jul-Aug;22(4):246-53 - PubMed
  13. Psychol Bull. 1992 Jul;112(1):155-9 - PubMed
  14. Asia Pac J Clin Nutr. 2013;22(2):171-6 - PubMed
  15. Trials. 2009 Aug 26;10:78 - PubMed
  16. Aging Cell. 2014 Jun;13(3):391-400 - PubMed
  17. Diabetes Care. 2003 Oct;26(10):2822-8 - PubMed
  18. Am J Psychiatry. 1997 Nov;154(11):1593-8 - PubMed
  19. Curr Diabetes Rev. 2014 Mar;10(2):113-7 - PubMed
  20. Psychosom Med. 2014 Jan;76(1):12-9 - PubMed
  21. Horm Metab Res. 1997 Jul;29(7):355-7 - PubMed
  22. Epidemiol Perspect Innov. 2011 Feb 02;8(1):1 - PubMed
  23. Free Radic Res. 2008 Oct;42(10):831-40 - PubMed
  24. Psychosom Med. 2014 Apr;76(3):181-9 - PubMed
  25. Mol Metab. 2013 Oct 05;2(4):356-63 - PubMed
  26. Int J Obes Relat Metab Disord. 2004 Aug;28(8):1004-10 - PubMed
  27. Acta Diabetol. 2003 Jun;40(2):95-100 - PubMed
  28. Biochim Biophys Acta. 2014 Feb;1840(2):801-8 - PubMed
  29. Ann N Y Acad Sci. 2012 Apr;1253:16-36 - PubMed
  30. Diabetes Care. 2010 Apr;33(4):926-30 - PubMed
  31. Diabet Med. 2010 Nov;27(11):1295-301 - PubMed
  32. Interface Focus. 2014 Oct 6;4(5):20140040 - PubMed
  33. Diabetes Care. 2015 Apr;38(4):551-60 - PubMed
  34. Diabetes. 2013 Oct;62(10 ):3307-15 - PubMed
  35. Psychotherapy (Chic). 2010 Dec;47(4):603-15 - PubMed
  36. Mol Psychiatry. 2015 Feb;20(1):32-47 - PubMed
  37. Diabetologia. 2012 Sep;55(9):2319-26 - PubMed
  38. Psychosom Med. 2009 Sep;71(7):715-24 - PubMed
  39. Med Care. 2003 Nov;41(11):1284-92 - PubMed
  40. Free Radic Biol Med. 2011 Oct 15;51(8):1473-9 - PubMed
  41. Metabolism. 2008 Feb;57(2):170-6 - PubMed
  42. Eur Rev Med Pharmacol Sci. 2014;18(9):1295-306 - PubMed
  43. Diabetologia. 2012 Mar;55(3):608-16 - PubMed
  44. Clin Biochem. 2006 Jul;39(7):667-81 - PubMed
  45. Diabet Med. 2006 Nov;23(11):1165-73 - PubMed
  46. Diabetes Care. 2000 Jul;23(7):934-42 - PubMed
  47. Diabetes Care. 2007 Jun;30(6):1473-9 - PubMed
  48. Am J Epidemiol. 2005 Apr 1;161(7):652-60 - PubMed
  49. Trials. 2011 Jan 21;12:17 - PubMed
  50. BMJ. 2005 Oct 15;331(7521):884 - PubMed
  51. Psychoneuroendocrinology. 2013 Sep;38(9):1698-708 - PubMed
  52. Diabetes Care. 2014 Aug;37(8):2186-92 - PubMed
  53. Oxid Med Cell Longev. 2012;2012:741545 - PubMed
  54. Exp Diabetes Res. 2012;2012:271028 - PubMed
  55. Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):640-6 - PubMed
  56. J Psychosom Res. 2013 Nov;75(5):419-24 - PubMed
  57. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008381 - PubMed
  58. Psychosom Med. 2006 Jan-Feb;68(1):1-7 - PubMed
  59. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):784-94 - PubMed

Publication Types